PB0452 - Glycemic Control and Plasma Levels of Pro-Inflammatory and Pro-Thrombotic Biomarkers in Diabetic Patients Presenting with Acute Pulmonary Embolism.

Sunday, June 25, 2023

18:30 – 19:30 ET

Room: Exhibition

Co-Author(s)

Bulent Kantarcioglu, MD

MD
Loyola University Chicago
Chicago, Illinois, United States

Co-Author(s)

AO

Alexander O’Hara

BSc
Loyola University Chicago
Chicago, Illinois, United States
JP

Jacob Pozin

BSc
Loyola University Chicago
Chicago, Illinois, United States
AD

Amir Darki

Associate Professor
Loyola University Chicago
Chicago, Illinois, United States

Presenting Author(s)

Fakiha Siddiqui, PhD Candidate

PhD Candidate
Department of Pathology and Laboratory Medicine, Cardiovascular Research Institute, Loyola University Chicago, Health Sciences Division, Maywood, IL, USA.
Maywood, Illinois, United States

Co-Author(s)

DH

Debra Hoppensteadt

Professor
Loyola University Chicago
Chicago, Illinois, United States
JW

Jeanine Walenga

Professor
Loyola University Chicago
Chicago, Illinois, United States
JF

Jawed Fareed, n/a

Professor
Loyola University Medical Center
MAYWOOD, Illinois, United States

Background: Type I and type II diabetes are closely associated with a pro-inflammatory state and to a pro-thrombotic state. The role of glycemic control in this disease process is poorly understood and requires additional investigation.

Aims: Our study attempts to better characterize the complex relationship between glucose regulation in diabetic patients who have experienced a pulmonary embolism and the levels of these circulating systemic and pro-thrombotic inflammatory biomarkers.

Methods: Demographic and clinical information for 86 diabetic patients and 106 non-diabetic patients presenting with acute pulmonary embolism (PE) was collected via retrospective chart review. Plasma levels of pro-inflammatory (CRP, TNF-a, IL-6) and pro-thrombotic (D-Dimer, PAI-1, tPA, TAFI, VWF, endogenous GAGs) biomarkers were drawn within 24 hours of diagnosis of acute PE. Data was also obtained for a population of healthy adult controls.

Results: All of the pro-inflammatory and pro-thrombotic biomarkers were elevated in diabetic PE patients in comparison to healthy controls. As shown on the Table -1, none of the biomarkers were elevated when compared to non-diabetic PE patients. There was no difference in the levels of the pro-inflammatory biomarkers according to glycemic control. The plasma levels of TAFI was elevated in diabetic patients with poor glycemic control (Table 2). Diabetic patients were more likely to have a more severe PE.

Conclusion(s): These studies demonstrate that thrombo-inflammatory biomarkers are elevated in diabetic PE patients with associated comorbidities in comparison to normal individuals. However, there is no difference between the PE cohort alone in comparison to PE with diabetes. The role of TAFI within the continuum of diabetic vascular disease warrants additional investigation.